Tag:
Valstar
Latest Headlines
Latest Headlines
ALSO NOTED: FDA says no to Indevus; Nektar gets sweetened deal with Baxter; Akela pulls public offering; and much more...
> Indevus Pharmaceuticals says that the FDA has turned thumbs down on its new therapy for bladder cancer, a move that trimmed its stock value. Valstar was pulled from the market five years ago
Indevus gets approvable letter
The FDA has handed an approvable letter to Indevus Pharmaceuticals for VALSTAR, a sterile solution of valrubicin for intravesical instillation for the treatment of bacillus Calmette-Guerin-refractory
Indevus gets approvable letter
Indevus got a preliminary FDA nod on Valstar, its bladder cancer therapy. The drug had been taken off the market in 2002 because of "impurities" in the original formula; since then, the
